Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Landmark study of cancer treatment with hyperthermia therapy is published

BSD Medical : 02 April, 2008  (Company News)
BSD Medical has welcomed the International Journal of Radiation Oncology, Biology and Physics’ publication of a seven-page report containing the 12-year clinical follow-up data for a landmark study comparing the clinical results for advanced cervical cancer patients treated with radiation and hyperthermia therapy to those for patients treated with radiation alone.
The publication is the official journal of the American Society for Therapeutic Radiology and Oncology (ASTRO), the world’s leading organization devoted to radiation oncology.

The article entitled, ‘Long-Term Improvement in Treatment Outcome after Radiotherapy and Hyperthermia in Loco-regionally Advanced Cervical Cancer: an Update of the Dutch Deep Hyperthermia Trial’, is considered highly relevant by BSD Medical because the follow-up data test the durability of the effect of hyperthermia therapy for cervical cancer patients. The original study was a Phase III clinical trial involving 358 patients with locally advanced pelvic tumours conducted at the University Hospital of Daniel den Hoed Cancer Center in Rotterdam and the Academic Medical Center in Amsterdam. The lead author in this study was Jacoba van der Zee, MD, PhD. The Dutch Health Insurance Council funded the study.

The 114 cervical cancer patients enrolled in the study had tumours that were loco-regionally advanced, and their prognosis was generally grave. The primary endpoints for the study were complete response and local control of the cancer. The secondary endpoints of the study were overall survival and toxic effects from radiation or hyperthermia.

In April 2000 the Lancet published the 3-year data from the study. For the cervical cancer patients, the data showed a complete-response rate of 83 percent for patients receiving both hyperthermia and radiation therapy as compared to 57 percent for those receiving radiation alone (p equals 0.003).

The published article also noted that ‘the improved local-control rates were not accompanied by increased toxic effects from radiation’. Survival follow-up data showed a 51 percent survival rate for patients who received radiation plus hyperthermia therapy, as compared to 27 percent of those who received radiation therapy alone (Lancet vol. 355, pp. 1119-1125).

According to the new publication, after 12 years local control remained significantly better for the cervical cancer patients who received hyperthermia therapy along with radiation - local control of 56 percent for that group as compared to 37 percent for those who received radiation therapy alone (p equals 0.01). After 12 years the survival rate was also persistently better for those patients who received hyperthermia therapy along with radiation, with a 37 percent survival rate for those patients as compared to a 20 percent survival rate for the patients who received radiation alone (p equals0.03). The new article concludes: “For loco-regionally advanced cervical cancer, the addition of hyperthermia therapy to radiation therapy resulted in long-term major improvement in local control and survival without increasing late toxicity.”

The new ASTRO publication offers the following rationale for the use of hyperthermia therapy with radiation therapy: ‘Hyperthermia, the artificial increase in tissue temperature to 40 to 44 degrees C, is an effective cytotoxic agent, especially in cells that are in a hypoxic nutrient-deprived low-pH environment. These conditions are commonly found in malignant tumours and make cells relatively resistant to radiation therapy. In addition to directly killing cells at temperatures of 40 to 44 degrees C, hyperthermia therapy also increases the cytotoxic effect of radiation therapy. Experimental studies show that it interfered with the cellular repair of radiation-induced DNA damage, thereby enhancing the cytotoxic effect of radiation therapy. Hyperthermia also increases blood flow, which may improve tissue oxygenation and make cells more sensitive to radiation therapy’ (see Int J Radiation Oncology Biol Phys, Vol 70, No. 4, pp 1176-1182, 2008).
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo